FN3: a new protein scaffold reaches the clinic.
paper
Cited
Public
Unavailable
- Authors
- Bloom, Laird; Calabro, Valerie
- Year
- 2009
- Journal
- Drug discovery today
- PMID
- 19576999
- DOI
- 10.1016/j.drudis.2009.06.007
In the ten years since the first fibronectin type III (FN3) domain library was published, FN3 has continued to show promise as a scaffold for the generation of stable protein domains that bind to targets with high affinity. A variety of display systems, library designs and affinity maturation strategies have been used to generate FN3 domains with nanomolar to picomolar affinities. The first crystal structures of engineered FN3 molecules in complex with their targets have been solved, and structural studies of engineered FN3 have begun to reveal determinants of stability and to define zones that accept mutations with minimal trade-off between affinity and stability. CT-322, the first engineered FN3 to enter clinical development, is now entering Phase II trials for glioblastoma multiforme.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A genome-wide association study of DSM-IV cannabis dependence. | 2011 | 21668797 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Binding mechanism of adenylate kinase-specific monobodies. | Nakamura I et al. | β | 2025 | β |
| Computational modeling and experimental validation of the interaction between tumor biomarker mesothelin and an engineered targeting protein with therapeutic activity. | Piccardi M et al. | β | 2025 | β |
| Inducible tag-free degradation of endogenous proteins with AlissAID and development of a photoactivable inducer. | Ogawa Y et al. | β | 2025 | β |
| Therapeutic potential of TRIM family proteins in gastric cancer: from signaling pathway regulation to precision targeting strategies. | Zhao C et al. | β | 2025 | β |
| Designing artificial fluorescent proteins and biosensors by genetically encoding molecular rotor-based amino acids. | Hu L et al. | β | 2024 | β |
| Engineering of an EPHA2-Targeted Monobody for the Detection of Colorectal Cancer. | Venu A et al. | β | 2024 | β |
| Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders. | Buzas D et al. | β | 2024 | β |
| Exploring the Mechanisms, Biomarkers, and Therapeutic Targets of TRIM Family in Gastrointestinal Cancer. | Weng C et al. | β | 2024 | β |
| Unique Fn3-like biosensor in Ο<sup>I</sup>/anti-Ο<sup>I</sup> factors for regulatory expression of major cellulosomal scaffoldins in Pseudobacteroides cellulosolvens. | Dong S et al. | β | 2024 | β |
| Deciphering roles of TRIMs as promising targets in hepatocellular carcinoma: current advances and future directions. | Zhang J et al. | β | 2023 | β |
| Development of AlissAID system targeting GFP or mCherry fusion protein. | Ogawa Y et al. | β | 2023 | β |
| Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders | Buzas D et al. | β | 2023 | β |
| A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. | Duan Q et al. | β | 2022 | β |
| Monobody adapter for functional antibody display on nanoparticles for adaptable targeted delivery applications. | Albert C et al. | β | 2022 | β |
| Probing the structure and function of polymerase ΞΈ helicase-like domain. | Vanson S et al. | β | 2022 | β |
| Using the Cyclotide Scaffold for Targeting Biomolecular Interactions in Drug Development. | Jacob B et al. | β | 2022 | β |
| DAKS1, a Kunitz Scaffold Peptide from the Venom Gland of <i>Deinagkistrodon acutus</i> Prevents Carotid-Artery and Middle-Cerebral-Artery Thrombosis via Targeting Factor XIa. | Jia Z et al. | β | 2021 | β |
| Directing evolution of novel ligands by mRNA display. | Kamalinia G et al. | β | 2021 | β |
| Engineering Calreticulin-Targeting Monobodies to Detect Immunogenic Cell Death in Cancer Chemotherapy. | Zhang Y et al. | β | 2021 | β |
| FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein. | Miller CJ et al. | β | 2021 | β |
| FN3 Domain Displaying Double Epitopes: A Cost-Effective Strategy for Producing Substitute Antigens. | Ruan Y et al. | β | 2021 | β |
| Monobodies as tool biologics for accelerating target validation and druggable site discovery. | Akkapeddi P et al. | β | 2021 | β |
| Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. | Zhong X et al. | β | 2021 | β |
| Revisiting the phosphotyrosine binding pocket of Fyn SH2 domain led to the identification of novel SH2 superbinders. | Li S et al. | β | 2021 | β |
| The Drosophila septate junctions beyond barrier function: Review of the literature, prediction of human orthologs of the SJ-related proteins and identification of protein domain families. | Rouka E et al. | β | 2021 | β |
| Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain. | Chandler PG et al. | β | 2020 | β |
| Engineered Protein Scaffolds as Next-Generation Therapeutics. | Gebauer M et al. | β | 2020 | β |
| Mammalian Expression and <i>In Situ</i> Biotinylation of Extracellular Protein Targets for Directed Evolution. | Grindel BJ et al. | β | 2020 | β |
| Production of <sup>64</sup>Cu-labeled monobody for imaging of human EphA2-expressing tumors. | Pyo A et al. | β | 2020 | β |
| Strategic design to create HER2-targeting proteins with target-binding peptides immobilized on a fibronectin type III domain scaffold. | Yimchuen W et al. | β | 2020 | β |
| Structural modeling, mutation analysis, and <i>in vitro</i> expression of usherin, a major protein in inherited retinal degeneration and hearing loss. | Yu D et al. | β | 2020 | β |
| Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives. | CzerwiΕska M et al. | β | 2020 | β |
| Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1. | Ramakrishnan S et al. | β | 2019 | β |
| The Potential of the Cyclotide Scaffold for Drug Development. | Camarero JA et al. | β | 2019 | β |
| Toxin Neutralization Using Alternative Binding Proteins. | Jenkins TP et al. | β | 2019 | β |
| Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions. | Chaudhuri D et al. | β | 2019 | β |
| Artificially Expanded Genetic Information Systems for New Aptamer Technologies. | Biondi E et al. | β | 2018 | β |
| Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display. | KΓΆnning D et al. | β | 2018 | β |
| Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding. | Sirois AR et al. | β | 2018 | β |
| Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function. | Lau SY et al. | β | 2018 | β |
| VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells. | Kulemzin SV et al. | β | 2018 | β |
| Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis. | Yu X et al. | β | 2017 | β |
| Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation. | Li D et al. | β | 2017 | β |
| Engineering of monobody conjugates for human EphA2-specific optical imaging. | Kim MA et al. | β | 2017 | β |
| Monobodies and other synthetic binding proteins for expanding protein science. | Sha F et al. | β | 2017 | β |
| A current perspective on applications of macrocyclic-peptide-based high-affinity ligands. | Leenheer D et al. | β | 2016 | β |
| Crystal structure and interaction studies of the human FBxo3 ApaG domain. | Krzysiak TC et al. | β | 2016 | β |
| Engineered Autonomous Human Variable Domains. | Nilvebrant J et al. | β | 2016 | β |
| FNDC3B promotes cell migration and tumor metastasis in hepatocellular carcinoma. | Lin CH et al. | β | 2016 | β |
| High Affinity Recognition of a Selected Amino Acid Epitope within a Protein by Cucurbit[8]uril Complexation. | Sonzini S et al. | β | 2016 | β |
| Proapoptotic RYBP interacts with FANK1 and induces tumor cell apoptosis through the AP-1 signaling pathway. | Ma W et al. | β | 2016 | β |
| Protein engineering strategies with potential applications for altering clinically relevant cellular pathways at the protein level. | Regan L et al. | β | 2016 | β |
| Antibody-mediated neutralization of perfringolysin o for intracellular protein delivery. | Yang NJ et al. | β | 2015 | β |
| Applications of Yeast Surface Display for Protein Engineering. | Cherf GM et al. | β | 2015 | β |
| Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations. | Hu J et al. | β | 2015 | β |
| Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2. | Park SH et al. | β | 2015 | β |
| PCSK9 inhibition in patients with hypercholesterolemia. | Desai NR et al. | β | 2015 | β |
| Streamlining the Pipeline for Generation of Recombinant Affinity Reagents by Integrating the Affinity Maturation Step. | Huang R et al. | β | 2015 | β |
| Structural and dynamic properties that govern the stability of an engineered fibronectin type III domain. | Porebski BT et al. | β | 2015 | β |
| Structural features of interfacial tyrosine residue in ROBO1 fibronectin domain-antibody complex: Crystallographic, thermodynamic, and molecular dynamic analyses. | Nakayama T et al. | β | 2015 | β |
| A new reagent for stable thiol-specific conjugation. | Badescu G et al. | β | 2014 | β |
| Converting a binding protein into a biosensing conformational switch using protein fragment exchange. | Zheng H et al. | β | 2014 | β |
| Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains. | Chen W et al. | β | 2014 | β |
| Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. | Jost C et al. | β | 2014 | β |
| Fast photochemical oxidation of proteins (FPOP) maps the epitope of EGFR binding to adnectin. | Yan Y et al. | β | 2014 | β |
| Hereditary myopathy with early respiratory failure is associated with misfolding of the titin fibronectin III 119 subdomain. | Hedberg C et al. | β | 2014 | β |
| PEGylation and its impact on the design of new protein-based medicines. | Ginn C et al. | β | 2014 | β |
| Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions. | Diem MD et al. | β | 2014 | β |
| Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development. | Kovaleva M et al. | β | 2014 | β |
| Stabilization of the third fibronectin type III domain of human tenascin-C through minimal mutation and rational design. | Gilbreth RN et al. | β | 2014 | β |
| Targeting PCSK9 for hypercholesterolemia. | Norata GD et al. | β | 2014 | β |
| Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing. | Portnoff AD et al. | β | 2014 | β |
| A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma. | Natarajan A et al. | β | 2013 | β |
| IGSF9 family proteins. | Hansen M et al. | β | 2013 | β |
| Ski2-like RNA helicase structures: common themes and complex assemblies. | Johnson SJ et al. | β | 2013 | β |
| The fibronectin-binding motif within FlpA facilitates Campylobacter jejuni adherence to host cell and activation of host cell signaling. | Larson CL et al. | β | 2013 | β |
| Knottins: disulfide-bonded therapeutic and diagnostic peptides. | β | β | 2012 | β |
| Phosphotyrosine recognition domains: the typical, the atypical and the versatile. | Kaneko T et al. | β | 2012 | β |
| ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. | Ou SH et al. | β | 2012 | β |
| Single-round, multiplexed antibody mimetic design through mRNA display. | Olson CA et al. | β | 2012 | β |
| Site-specific PEGylation at histidine tags. | Cong Y et al. | β | 2012 | β |
| Structures of adnectin/protein complexes reveal an expanded binding footprint. | Ramamurthy V et al. | β | 2012 | β |
| Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. | Koide A et al. | β | 2012 | β |
| Unexpected multivalent display of proteins by temperature triggered self-assembly of elastin-like polypeptide block copolymers. | Hassouneh W et al. | β | 2012 | β |
| Adnectins: engineered target-binding protein therapeutics. | Lipovsek D | β | 2011 | β |
| A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. | Emanuel SL et al. | β | 2011 | β |
| A genome-wide association study of DSM-IV cannabis dependence. | Agrawal A et al. | β | 2011 | β |
| Alternative affinity tools: more attractive than antibodies? | Ruigrok VJ et al. | β | 2011 | β |
| Chimeric fibronectin matrix mimetic as a functional growth- and migration-promoting adhesive substrate. | Roy DC et al. | β | 2011 | β |
| Highly stable binding proteins derived from the hyperthermophilic Sso7d scaffold. | Gera N et al. | β | 2011 | β |
| Rapid mRNA-display selection of an IL-6 inhibitor using continuous-flow magnetic separation. | Olson CA et al. | β | 2011 | β |
| Cyclotides, a promising molecular scaffold for peptide-based therapeutics. | Jagadish K et al. | β | 2010 | β |
| Ion-specific effects on the interaction between fibronectin and negatively charged mica surfaces. | Heath MD et al. | β | 2010 | β |